ONC Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

13 Analyst Rating

Wall Street analysts forecast ONC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ONC is 397.66 USD with a low forecast of 362.00 USD and a high forecast of 424.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

12 Buy

1 Hold

0 Sell

Strong Buy

Current: 310.670

Low

362.00

Averages

397.66

High

424.00

Current: 310.670

Low

362.00

Averages

397.66

High

424.00

Truist

Buy

initiated

$400

2025-11-24

Reason

Truist

Price Target

$400

2025-11-24

initiated

Buy

Reason

Truist initiated coverage of BeOne Medicines with a Buy rating and $400 price target. The firm expect Brukinsa's revenue stream to sustainably support the company's operations and drive BeOne Medicines toward the guided positive free cash flow by 2025, the analyst tells investors in a research note. The company's leadership position in CLL - chronic lymphocytic leukemia - is well-solidified by Brukinsa's differentiation and the franchise's comprehensive growth strategy, including proprietary next-wave assets such as sonrotoclax and BTK CDAC, Truist added.

RBC Capital

Outperform

maintain

$395 -> $408

2025-11-18

Reason

RBC Capital

Price Target

$395 -> $408

2025-11-18

maintain

Outperform

Reason

RBC Capital raised the firm's price target on BeOne Medicines to $408 from $395 and keeps an Outperform rating on the shares. The Ziihera phase III HORIZON-GEA update clears the way for a potential 1L approval in combination with Tevimbra and chemotherapy and adds incremental upside to shares, the analyst tells investors in a research note.

Morgan Stanley

Sean Laaman

Overweight

maintain

$185 -> $205

2025-11-17

Reason

Morgan Stanley

Sean Laaman

Price Target

$185 -> $205

2025-11-17

maintain

Overweight

Reason

Morgan Stanley analyst Sean Laaman raised the firm's price target on Jazz Pharmaceuticals (JAZZ) to $205 from $185 and keeps an Overweight rating on the shares. Jazz reported positive topline results for the HERIZON-GEA-01 trial evaluating Ziihera, a bispecific HER2-directed antibody, in combination with chemotherapy, with or without BeOne Medicine's (ONC) PD-1 inhibitor Tevimbra, as first-line treatment for HER2-positive locally advanced or metastatic GEA, but and while limited details were provided, Jazz indicated a highly competitive profile ahead of the sBLA submission in 1H26, the analyst tells investors in a research note. Ziihera plus chemotherapy and Ziihera plus tislelizumab and chemotherapy demonstrated highly statistically significant and clinically meaningful improvements in progression-free survival compared to the control arm, positioning Ziihera as a potential new standard of care for first-line HER2-positive GEA, replacing trastuzumab in this setting, the firm says.

Jefferies

Buy

maintain

$398 -> $420

2025-11-17

Reason

Jefferies

Price Target

$398 -> $420

2025-11-17

maintain

Buy

Reason

Jefferies raised the firm's price target on BeOne Medicines to $420 from $398 and keeps a Buy rating on the shares following a fireside chat and investor breakfast with management in London. The firm notes that management believes its chronic lymphocytic leukemia franchise will deliver "best-in-class" therapy to the full spectrum of CLL market. BeOne is advancing solid tumor pipeline at full speed with data in 2026, Jefferies told investors in a research note.

Citi

Buy

maintain

$399 -> $405

2025-11-09

Reason

Citi

Price Target

$399 -> $405

2025-11-09

maintain

Buy

Reason

Citi raised the firm's price target on BeOne Medicines to $405 from $399 and keeps a Buy rating on the shares. The company reported a strong quarter, topping estimates for Brukinsa, the analyst tells investors in a research note.

Morgan Stanley

Sean Laaman

Overweight

maintain

$383 -> $390

2025-11-07

Reason

Morgan Stanley

Sean Laaman

Price Target

$383 -> $390

2025-11-07

maintain

Overweight

Reason

Morgan Stanley analyst Sean Laaman raised the firm's price target on BeOne Medicines to $390 from $383 and keeps an Overweight rating on the shares. Brukinsa came in above Street expectations with the bottom end of total revenue guidance raised to $5.1B-$5.3B, the analyst tells investors in a research note. The firm added that BeOne provided updates across its pipeline, with updated data expected at ASH in December.

Valuation Metrics

The current forward P/E ratio for BeOne Medicines AG (ONC.O) is 70.30, compared to its 5-year average forward P/E of 79.40. For a more detailed relative valuation and DCF analysis to assess BeOne Medicines AG 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

79.40

Current PE

70.30

Overvalued PE

155.79

Undervalued PE

3.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

24.52

Current EV/EBITDA

41.25

Overvalued EV/EBITDA

66.92

Undervalued EV/EBITDA

-17.88

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

6.08

Current PS

5.83

Overvalued PS

7.02

Undervalued PS

5.14

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 7307.41% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ONC News & Events

Events Timeline

No data

News

5.0

12-14Barron's

Kymera Stock Soars as Secretive Hedge Fund Acquires $172 Million Stake.

3.5

12-08Newsfilter

BeOne Showcases BRUKINSA's Leadership in CLL Treatment at ASH 2025

9.0

12-07Businesswire

BeOne Medicines Presents 52.4% Efficacy of Sonrotoclax at ASH Meeting

People Also Watch

Frequently Asked Questions

What is BeOne Medicines AG (ONC) stock price today?

The current price of ONC is 310.67 USD — it has decreased -2.63 % in the last trading day.

What is BeOne Medicines AG (ONC)'s business?

BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.

What is the price predicton of ONC Stock?

What is BeOne Medicines AG (ONC)'s revenue for the last quarter?

BeOne Medicines AG revenue for the last quarter amounts to 1.41B USD, increased 41.00 % YoY.

What is BeOne Medicines AG (ONC)'s earnings per share (EPS) for the last quarter?

BeOne Medicines AG. EPS for the last quarter amounts to 0.08 USD, decreased -188.89 % YoY.

What changes have occurred in the market's expectations for BeOne Medicines AG (ONC)'s fundamentals?

The market is revising Downward the revenue expectations for BeOne Medicines AG (ONC) for FY2025, with the revenue forecasts being adjusted by -0.3% over the past three months. During the same period, the stock price has changed by -6.50%.

How many employees does BeOne Medicines AG (ONC). have?

BeOne Medicines AG (ONC) has 11000 emplpoyees as of December 15 2025.

What is BeOne Medicines AG (ONC) market cap?

Today ONC has the market capitalization of 37.81B USD.